MA30556B1 - COMPOSES A BASE DE DIALKYLPHENYLE AYANT UNE ACTIVITE AGONISTE DU RECEPTEUR ADRENERGIQUE ß2 ET ANTAGONISTE DU RECEPTEUR MUSCARINIQUE. - Google Patents

COMPOSES A BASE DE DIALKYLPHENYLE AYANT UNE ACTIVITE AGONISTE DU RECEPTEUR ADRENERGIQUE ß2 ET ANTAGONISTE DU RECEPTEUR MUSCARINIQUE.

Info

Publication number
MA30556B1
MA30556B1 MA31382A MA31382A MA30556B1 MA 30556 B1 MA30556 B1 MA 30556B1 MA 31382 A MA31382 A MA 31382A MA 31382 A MA31382 A MA 31382A MA 30556 B1 MA30556 B1 MA 30556B1
Authority
MA
Morocco
Prior art keywords
receptor
dialkylphenyl
antagonist
based compounds
compounds
Prior art date
Application number
MA31382A
Other languages
English (en)
Inventor
Pierre-Jean Colson
Adam Hughes
Craig Husfeld
Mathai Mammen
Miroslav Rapta
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of MA30556B1 publication Critical patent/MA30556B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

La présente invention concerne des composés de formule I, dans laquelle: R1 et R2 sont tels que définis dans la spécification, ou un sel ou solvate ou stéréoisomère pharmaceutiquement acceptable de celui-ci. L'invention concerne également des compositions et combinaisons pharmaceutiques comportant de tels composés, des procédés et des intermédiaires pour préparer de tels composés, et des procédés d'utilisation de tels composés par exemple, pour traiter des troubles pulmonaires, tels que la maladie pulmonaire obstructive chronique et l'asthme.
MA31382A 2006-04-25 2008-11-14 COMPOSES A BASE DE DIALKYLPHENYLE AYANT UNE ACTIVITE AGONISTE DU RECEPTEUR ADRENERGIQUE ß2 ET ANTAGONISTE DU RECEPTEUR MUSCARINIQUE. MA30556B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79470206P 2006-04-25 2006-04-25

Publications (1)

Publication Number Publication Date
MA30556B1 true MA30556B1 (fr) 2009-07-01

Family

ID=38577470

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31382A MA30556B1 (fr) 2006-04-25 2008-11-14 COMPOSES A BASE DE DIALKYLPHENYLE AYANT UNE ACTIVITE AGONISTE DU RECEPTEUR ADRENERGIQUE ß2 ET ANTAGONISTE DU RECEPTEUR MUSCARINIQUE.

Country Status (20)

Country Link
US (3) US7524965B2 (fr)
EP (1) EP2010489B1 (fr)
JP (1) JP2009541209A (fr)
KR (1) KR20090005389A (fr)
CN (1) CN101426764A (fr)
AR (1) AR060647A1 (fr)
AU (1) AU2007243481A1 (fr)
BR (1) BRPI0710767A2 (fr)
CA (1) CA2650530A1 (fr)
CO (1) CO6140054A2 (fr)
ES (1) ES2391584T3 (fr)
IL (1) IL194334A0 (fr)
MA (1) MA30556B1 (fr)
MX (1) MX2008013555A (fr)
NO (1) NO20084603L (fr)
PE (1) PE20080094A1 (fr)
RU (1) RU2008146383A (fr)
TW (1) TW200811105A (fr)
WO (1) WO2007127196A2 (fr)
ZA (1) ZA200808817B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6693202B1 (en) * 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
US7528253B2 (en) * 2004-08-16 2009-05-05 Theravance, Inc. Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity
TW200811104A (en) * 2006-04-25 2008-03-01 Theravance Inc Crystalline forms of a dimethylphenyl compound
TW200811105A (en) * 2006-04-25 2008-03-01 Theravance Inc Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
EP2242759B1 (fr) * 2008-02-06 2012-09-12 AstraZeneca AB Composés
MY158339A (en) 2009-04-23 2016-09-30 Theravance Respiratory Co Llc DIAMIDE COMPOUNDS HAVING MUSCARING RECEPTOR ANTAGONIST AND ß2 ADRENERGIC RECEPTOR AGONIST ACTIVITY
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
PL3061821T3 (pl) 2009-07-22 2020-01-31 PureTech Health LLC Kompozycje do leczenia zaburzeń łagodzonych przez aktywację receptora muskarynowego
WO2011081937A1 (fr) 2009-12-15 2011-07-07 Gilead Sciences, Inc. Composés de type corticostéroïde-bêta-agoniste-antagoniste muscarinique pour applications thérapeutiques
GB201009801D0 (en) 2010-06-11 2010-07-21 Astrazeneca Ab Compounds 950
MX2021003621A (es) 2018-09-28 2022-04-13 Karuna Therapeutics Inc Composiciones y metodos para tratar trastornos mejorados por medio de activacion de receptor muscarinico.
CN114409556A (zh) * 2022-01-28 2022-04-29 兰州康鹏威耳化工有限公司 一种3,4-二取代-2-氨基苯甲醛的制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7545894A (en) 1993-09-02 1995-03-22 Yamanouchi Pharmaceutical Co., Ltd. Carbamate derivative and medicine containing the same
HUT76289A (en) 1994-02-10 1997-07-28 Yamanouchi Pharma Co Ltd Carbamate derivative and medicinal composition containing the same
US6040344A (en) 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
US6541669B1 (en) * 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
US6693202B1 (en) 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
DE19921693A1 (de) 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
UA73965C2 (en) 1999-12-08 2005-10-17 Theravance Inc b2 ADRENERGIC RECEPTOR ANTAGONISTS
ES2296923T3 (es) 2001-03-22 2008-05-01 Glaxo Group Limited Derivados formanilidas como agonistas del adrenorreceptor beta2.
US20030018019A1 (en) 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
CA2543858C (fr) * 2003-11-21 2014-04-15 Theravance, Inc. Composes ayant une activite agoniste de recepteur adrenergique beta 2 et antagoniste de recepteur muscarinique
WO2005087735A1 (fr) 2004-03-11 2005-09-22 Theravance, Inc. Utilisation de composes biphenyles comme antagonistes des recepteurs muscariniques
TWI374883B (en) 2004-08-16 2012-10-21 Theravance Inc Crystalline form of a biphenyl compound
EP1833822A2 (fr) 2004-08-16 2007-09-19 Theravance, Inc. Composes a activite agoniste pour recepteur beta2 adrenergique et antagoniste pour recepteur muscarinique
US7528253B2 (en) 2004-08-16 2009-05-05 Theravance, Inc. Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity
TW200811105A (en) 2006-04-25 2008-03-01 Theravance Inc Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
TW200811104A (en) * 2006-04-25 2008-03-01 Theravance Inc Crystalline forms of a dimethylphenyl compound

Also Published As

Publication number Publication date
EP2010489B1 (fr) 2012-08-22
CA2650530A1 (fr) 2007-11-08
US20090176833A1 (en) 2009-07-09
RU2008146383A (ru) 2010-05-27
PE20080094A1 (es) 2008-02-17
US8134006B2 (en) 2012-03-13
US20070249675A1 (en) 2007-10-25
AU2007243481A1 (en) 2007-11-08
US7524965B2 (en) 2009-04-28
EP2010489A2 (fr) 2009-01-07
US7687521B2 (en) 2010-03-30
JP2009541209A (ja) 2009-11-26
KR20090005389A (ko) 2009-01-13
WO2007127196A3 (fr) 2007-12-21
BRPI0710767A2 (pt) 2011-06-07
ZA200808817B (en) 2010-03-31
WO2007127196A2 (fr) 2007-11-08
IL194334A0 (en) 2009-08-03
NO20084603L (no) 2008-11-19
US20100137603A1 (en) 2010-06-03
CO6140054A2 (es) 2010-03-19
AR060647A1 (es) 2008-07-02
MX2008013555A (es) 2008-11-04
TW200811105A (en) 2008-03-01
ES2391584T3 (es) 2012-11-28
CN101426764A (zh) 2009-05-06

Similar Documents

Publication Publication Date Title
MA30556B1 (fr) COMPOSES A BASE DE DIALKYLPHENYLE AYANT UNE ACTIVITE AGONISTE DU RECEPTEUR ADRENERGIQUE ß2 ET ANTAGONISTE DU RECEPTEUR MUSCARINIQUE.
WO2006023460A3 (fr) Composes a activite agoniste pour recepteur ?2 adrenergique et antagoniste pour recepteur muscarinique
US7582672B2 (en) Compounds for the treatment of CRTH2-mediated diseases and conditions
TNSN07349A1 (fr) Derives de n-(n-sulfonylaminomethyl) cyclopropanecarboxamide utiles pour le traitement de la douleur
ATE435862T1 (de) Azabicycloalkanverbindungen als muscarinrezeptor antagonisten
MY158339A (en) DIAMIDE COMPOUNDS HAVING MUSCARING RECEPTOR ANTAGONIST AND ß2 ADRENERGIC RECEPTOR AGONIST ACTIVITY
WO2004074246A3 (fr) Derives de biphenyle
US20110245208A1 (en) Compositions and methods for the treatment of somatosensory disorders
MA31311B1 (fr) Dérivés d'indazole substitués par oxadiazole, destinés à être utilisés comme agonistes de la sphingosine 1-phosphate (s1p)
MA27779A1 (fr) FORME CRISTALLINE D'AGONISTE DE RECEPTEUR β2 ADRENERGIQUE
MA28432B1 (fr) Antagonistes du recepteur de la chimiokine
PL1735278T3 (pl) Związki receptora histaminowego H3, wytwarzanie i zastosowania terapeutyczne
MA28435B1 (fr) Composes d'indazole-carboxamide en tant qu'agonistes de recepteur 5-ht4
WO2004089892A3 (fr) Diarylmethyle et composes apparentes
MA30284B1 (fr) Composes de 8-azabicyclo[3.2.1]octane en tant qu'antagonistes du recepteur opioide mu
EA200701361A1 (ru) Конденсированные производные пиразола и способы лечения с их помощью заболеваний, вызванных нарушением обмена веществ
PH12014500937A1 (en) 5-ht 1a receptor substype agonist
WO2009063202A2 (fr) Utilisation de composés antagonistes de crth2
NO20075453L (no) Sammensetning inneholdende antidemensmiddel
WO2006038006A3 (fr) Nouveaux composes
MA29541B1 (fr) Composes benzimidazole-carboxamide utilises comme agonistes du recepteur 5-ht4
EA200601461A1 (ru) Новые производные бензил(иден)лактама
CY1109694T1 (el) Παραγωγα πυρρολιδινης ως ανταγωνιστες υποδοχεα η3 ισταμινης
EP1115404B1 (fr) Utilisation d'antagonistes de prostanoides pour le traitement de cephalees primaires
CN101400642A (zh) 具有中枢神经系统活性的环丙烷